TRCT
NRXPW

Tower Research Capital (TRC)’s NRX Pharmaceuticals Warrant NRXPW Stock Holding History

Tower Research Capital (TRC)’s Portfolio NRXPW Stock Details NRXPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15
Closed -$2 – 5608
2024
Q4 		$2 Hold
15
– – ﹤0.01% 5652
2024
Q3 		$1 Hold
15
– – ﹤0.01% 5677
2024
Q2 		$1 Hold
15
– – ﹤0.01% 5649
2024
Q1 		$3 Hold
15
– – ﹤0.01% 5805
2023
Q4 		$2 Hold
15
– – ﹤0.01% 5882
2023
Q3 		$1 Hold
15
– – ﹤0.01% 5915
2023
Q2 		$4 Hold
15
– – ﹤0.01% 5980
2023
Q1 		$0 Hold
15
– – ﹤0.01% 6135
2022
Q4 		$0 Hold
15
– – ﹤0.01% 6213
2022
Q3 		$0 Hold
15
– – ﹤0.01% 6348
2022
Q2 		$0 Hold
15
– – ﹤0.01% 6386
2022
Q1 		$0 Hold
15
– – ﹤0.01% 6418
2021
Q4 		$0 Hold
15
– – ﹤0.01% 6424
2021
Q3 		$0 Hold
15
– – ﹤0.01% 6039
2021
Q2 		$0 Buy
+15
New +$104 ﹤0.01% 5722

Other funds holding NRXPW

Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Tower Research Capital (TRC)'s NRXPW Position: Q1 2025 in Review

Tower Research Capital (TRC) sold out of NRX Pharmaceuticals Warrant (NRXPW) in Q1 2025, closing a stake of 15 shares — an estimated $2 sold.

Tower Research Capital (TRC) first reported a position in NRXPW in Q2 2021 and held it in 15 quarters. The position peaked at $4 in Q2 2023. 4 funds tracked by Wall St. Rank hold NRXPW as of Q1 2025.

  • Tower Research Capital (TRC) reported no remaining NRX Pharmaceuticals Warrant position as of Q1 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 15 NRX Pharmaceuticals Warrant shares in Q1 2025, an estimated $2.
  • Tower Research Capital (TRC) first reported a position in NRX Pharmaceuticals Warrant in Q2 2021 and held it in 15 quarters.
  • Tower Research Capital (TRC)'s NRX Pharmaceuticals Warrant position peaked at $4 in Q2 2023.
  • 4 funds tracked by Wall St. Rank held NRX Pharmaceuticals Warrant as of Q1 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2025, filed 15 May 2025.